Tower Research Capital (TRC)’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-77,282
| Closed | -$2.66M | – | 5637 |
|
|
2020
Q3 | $2.66M | Buy |
77,282
+61,204
| +381% | +$1.3M | 0.03% | 245 |
|
|
2020
Q2 | $269K | Buy |
+16,078
| New | +$273K | 0.01% | 1546 |
|
|
2019
Q4 | – | Sell |
-1,825
| Closed | -$38K | – | 4786 |
|
|
2019
Q3 | $38K | Buy |
+1,825
| New | +$37.3K | ﹤0.01% | 2007 |
|
|
2019
Q2 | – | Sell |
-370
| Closed | -$8K | – | 4626 |
|
|
2019
Q1 | $8K | Sell |
370
-1,470
| -80% | -$34.6K | ﹤0.01% | 2841 |
|
|
2018
Q4 | $44K | Buy |
1,840
+708
| +63% | +$18.3K | ﹤0.01% | 1373 |
|
|
2018
Q3 | $31K | Buy |
+1,132
| New | +$32K | ﹤0.01% | 2060 |
|
|
2018
Q1 | – | Sell |
-2,232
| Closed | -$84K | – | 4123 |
|
|
2017
Q4 | $84K | Sell |
2,232
-3,131
| -58% | -$101K | 0.01% | 979 |
|
|
2017
Q3 | $133K | Buy |
+5,363
| New | +$116K | 0.01% | 1096 |
|
|
2017
Q1 | – | Sell |
-1,235
| Closed | -$26K | – | 4266 |
|
|
2016
Q4 | $26K | Buy |
+1,235
| New | +$25.2K | ﹤0.01% | 1923 |
|
|
2016
Q3 | – | Sell |
-148
| Closed | -$2K | – | 4834 |
|
|
2016
Q2 | $2K | Sell |
148
-2,712
| -95% | -$36.8K | ﹤0.01% | 4028 |
|
|
2016
Q1 | $39K | Buy |
2,860
+2,541
| +797% | +$39.6K | 0.01% | 919 |
|
|
2015
Q4 | $6K | Sell |
319
-3,645
| -92% | -$67.4K | ﹤0.01% | 2862 |
|
|
2015
Q3 | $100K | Buy |
+3,964
| New | +$92.7K | 0.01% | 568 |
|
Tower Research Capital (TRC)'s AIMT Position: Q4 2020 in Review
Tower Research Capital (TRC) sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 77,282 shares — an estimated $2.66M sold.
Tower Research Capital (TRC) first reported a position in AIMT in Q3 2015 and held it in 13 quarters. The position peaked at $2.66M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Tower Research Capital (TRC) reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Tower Research Capital (TRC) sold 77,282 Aimmune Therapeutics shares in Q4 2020, an estimated $2.66M.
- Tower Research Capital (TRC) first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 13 quarters.
- Tower Research Capital (TRC)'s Aimmune Therapeutics position peaked at $2.66M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2020, filed 16 Feb 2021.